Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

GlaxoSmithKline plc (ADR) (GSK), An Emerging Market Investment?

So is GlaxoSmithKline a buy?
City analysts expect earnings per share to edge 2% higher in 2013, to 115 pence, before gaining traction thereafter — growth of 8%, to 125 pence, has been penciled in for 2014. The company is boosting R&D to counter the issue of IP expiration across many of its drugs, building a lucrative pipeline of new products to underpin long-term revenues, and six key compounds are currently undergoing regulatory testing.

The pharma giant has proved itself to be a reliable dividend builder in recent years, even in times of significant earnings pressure, and brokers expect last year’s 74 pence per share payout to increase to 78 pence per share and 81.9 pence per share this year and next. GlaxoSmithKline plc (ADR) (LSE:GSK) has also targeted between 1 billion pounds and 2 billion pounds of share buybacks this year to lift shareholder returns.

Prospective dividends for this year and next carry yields of 4.6% and 4.9%, far in excess of a forward dividend yield forecast of 2.4% for the entire pharmaceuticals and biotechnology sector, and above the FTSE 100’s 3.3% reading.

GlaxoSmithKline plc (ADR) (LSE:GSK) was recently dealing on a P/E ratio of 14.6 and 13.5 for 2013 and 2014, respectively, providing a massive discount to a prospective earnings multiple of 48 for the U.K.’s listed pharmaceuticals and biotechnology companies. I believe that improving earnings prospects, combined with a robust dividend policy, makes the pharma play an excellent stock pick.

The article Is GlaxoSmithKline an Exciting Emerging Market Play? originally appeared on and is written by Royston Wild.

Fool contributor Royston Wild has no position in any stocks mentioned. The Motley Fool recommends GlaxoSmithKline.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

DOWNLOAD FREE REPORT: Warren Buffett's Best Stock Picks

Let Warren Buffett, George Soros, Steve Cohen, and Daniel Loeb WORK FOR YOU.

If you want to beat the low cost index funds by 19 percentage points per year, look no further than our monthly newsletter.In this free report you can find an in-depth analysis of the performance of Warren Buffett's entire historical stock picks. We uncovered Warren Buffett's Best Stock Picks and a way to for Buffett to improve his returns by more than 4 percentage points per year.

Bonus Biotech Stock Pick: You can also find a detailed bonus biotech stock pick that we expect to return more than 50% within 12 months.
Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.